Sharechat Logo

Ebos deal with Chemist Warehouse could boost revenue by A$1B in first year

Monday 2nd July 2018

Text too small?

Ebos Group, the pharmaceutical and animal health products maker, says it's won a bid for a distribution deal with Australia's Chemist Warehouse which could bring in A$1 billion of revenue in the first year.

The two expect to sign a five-year supply agreement, starting July 2019, which could potentially be extended by three years, after Ebos won the tender to be the exclusive third-party distributor of pharmaceutical products to over 400 Chemist Warehouse and My Chemist stores in Australia. 

Ebos said it estimates that sales to the Chemist Warehouse Group stores will generate approximately A$1 billion in revenue in the first year of the agreement. In the six months to Dec. 31 2017, its profit was $76.7 million on revenue of $3.94 billion.

Ebos transformed itself in 2013 with the purchase of Australian pharmaceutical wholesaler and distributor Symbion, and has since bought New Zealand vitamin and herbal tea maker Red Seal, pharmaceuticals firm Zest, Australian pharmacy retailer Good Price Pharmacy Warehouse, the Black Hawk Premium Pet Care pet food business and merged its Australian Chemmart pharmacy chain with rival Terry White Group.

In May last year it bought Australia’s largest provider of outsourced pharmacy services to hospitals, HPS, for A$154 million and acquired a 14.1 percent shareholding in MedAdvisor Ltd, Australia’s leading digital medication management company, last October.

“It’s a great endorsement of Ebos’s wholesale pharmacy business, and reflects the high level of expertise and service standards that we offer the industry more broadly," said chief executive John Cullity. "Continuing to grow our healthcare business remains a high priority for the group and partnering with Chemist Warehouse Group will be a natural progression of that. We are confident that Ebos will generate an acceptable return on capital from this new business."

The company's shares rose 3.9 percent to $18.65, and have dipped 3.2 percent this year.


  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares gain; a2 hits new record, F&P climbs on patent deal
NZ dollar eases against Aussie on strong jobs data
KiwiSaver funds face unrealised capital gains tax on NZ and Aussie shares
Planning changes need to speed renewables development - Meridian
A guide to the Tax Working Group's 'other' recommendations
MYOB adds 57% more subscribers in 2018 but total online customers still lag Xero's
Investors fear chilling effect as former IRD boss opposes capital gains proposals
Stuff 1H earnings slide but Nine still optimistic of finding buyer
NZ Post achieves first-half revenue growth for the first time since 2015
TeamTalk affirms annual earnings guidance as rising costs dent first-half profit

IRG See IRG research reports